Bio-Techne Surges to 490th Most Traded Stock with 2.20 Billion Turnover

On May 8, 2025, Bio-Techne (TECH) experienced a significant surge in trading volume, with a turnover of 2.20 billion, marking a 30.6% increase from the previous day. This surge positioned Bio-Techne as the 490th most traded stock for the day, reflecting a notable rise in investor interest. The stock price also saw a 2.11% increase, continuing its upward trend for the second consecutive day, with a total gain of 4.32% over the past two days.

Prothena Corporation plc, a late-stage clinical biotechnology company, reported its financial results for the first quarter of 2025. The company reported a net loss of $60.2 million, a decrease from the $72.2 million net loss in the same period last year. Total revenue for the quarter was $2.8 million, primarily from collaboration revenue with Bristol Myers Squibb. Prothena's cash position stood at $418.8 million as of March 31, 2025, with no debt.

Prothena is anticipating several key clinical milestones in 2025. Topline results from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab for AL amyloidosis are expected in the second quarter of 2025. Additionally, multiple clinical readouts for PRX012, a potential treatment for early Alzheimer’s disease, are expected starting around mid-2025. Roche, Prothena's partner, presented data from the Phase 2b PADOVA clinical trial of prasinezumab for early Parkinson’s disease at AD/PD 2025, suggesting a possible benefit in early-stage Parkinson’s disease.

Prothena's pipeline includes several investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases. The company is advancing programs for AL amyloidosis, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, and Parkinson’s disease. Prothena's deep scientific expertise in protein dysregulation positions it to leverage insights around neurological dysfunction and the biology of misfolded proteins for novel therapeutic targets.